Pfizer’s RSV vaccine is the first of its kind and could become the first available maternal shot to protect babies from the illness. On Thursday, the U.S. Food and Drug Administration’s advisory committee voted unanimously that available data supported the vaccine’s efficacy and safety for giving the shot to women in their second or third trimesters of pregnancy. If approved, the vaccine could help protect infants up to 6 months of age from lower respiratory tract infection and severe disease.
Categories